Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China

被引:11
|
作者
Chen, Jing-Feng [1 ]
Wu, Zhuo-Qing [2 ]
Liu, Hao-Shuang [1 ]
Yan, Su [1 ]
Wang, You-Xiang [3 ]
Xing, Miao [4 ]
Song, Xiao-Qin [1 ]
Ding, Su-Ying [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Hlth Management Ctr, 1 Longhu Middle Ring Rd, Zhengzhou 450052, Henan, Peoples R China
[2] Dalian Univ Technol, Inst Syst Engn, Dalian 116024, Liaoning, Peoples R China
[3] Zhengzhou Univ, Coll Publ Hlth, Zhengzhou 450001, Henan, Peoples R China
[4] Henan Univ Sci & Technol, Sch Basic Med & Forens Med, Luoyang 471003, Henan, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Metabolic dysfunction-associated fatty liver disease; High-normal alanine aminotransferase level; Cumulative effect; Cox proportional hazards regression; Cohort study; LYMPH-NODE METASTASIS; ESOPHAGEAL; MORTALITY; NOMOGRAM;
D O I
10.3748/wjg.v30.i10.1346
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Within the normal range, elevated alanine aminotransferase (ALT) levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease (MAFLD). AIM To investigate the associations between repeated high-normal ALT measurements and the risk of new-onset MAFLD prospectively. METHODS A cohort of 3553 participants followed for four consecutive health examinations over 4 years was selected. The incidence rate, cumulative times, and equally and unequally weighted cumulative effects of excess high-normal ALT levels (ehALT) were measured. Cox proportional hazards regression was used to analyse the association between the cumulative effects of ehALT and the risk of new-onset MAFLD. RESULTS A total of 83.13% of participants with MAFLD had normal ALT levels. The incidence rate of MAFLD showed a linear increasing trend in the cumulative ehALT group. Compared with those in the low-normal ALT group, the multivariate adjusted hazard ratios of the equally and unequally weighted cumulative effects of ehALT were 1.651 [95% confidence interval (CI): 1.199-2.273] and 1.535 (95%CI: 1.119-2.106) in the third quartile and 1.616 (95%CI: 1.162-2.246) and 1.580 (95%CI: 1.155-2.162) in the fourth quartile, respectively. CONCLUSION Most participants with MAFLD had normal ALT levels. Long-term high-normal ALT levels were associated with a cumulative increased risk of new-onset MAFLD.
引用
收藏
页码:1346 / 1357
页数:13
相关论文
共 50 条
  • [1] Effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease: Clinical implications
    McGinty, Giovanna
    Przemioslo, Robert
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (27)
  • [2] Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease
    Wang, Di
    Zhou, Bing-Yan
    Xiang, Lei
    Chen, Xu-Yong
    Feng, Jie-Xiong
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (25) : 3132 - 3139
  • [3] Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test
    Moyana, Terence N.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (42)
  • [4] Normal serum alanine aminotransferase levels for screening metabolic dysfunction- associated fatty liver disease
    Yang, Junli
    Hou, Yeting
    Zhang, Qiang
    Wang, Yanfang
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (10) : 1092 - 1093
  • [5] Reply to: "Normal serum alanine aminotransferase levels for screening metabolic dysfunction associated fatty liver disease"
    Lin, Yu-Cheng
    Chang, Pi-Feng
    Ni, Yen-Hsuan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2023, 122 (10) : 1094 - 1095
  • [6] High-density lipoprotein cholesterol trajectory and new-onset metabolic dysfunction-associated fatty liver disease incidence: a longitudinal study
    Zhang, Mengting
    Chang, Dongchun
    Guan, Qing
    Dong, Rui
    Zhang, Ru
    Zhang, Wei
    Wang, Hongliang
    Wang, Jie
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [7] Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease
    Tanaka, Marenao
    Mori, Kazuma
    Takahashi, Satoko
    Higashiura, Yukimura
    Ohnishi, Hirofumi
    Hanawa, Nagisa
    Furuhashi, Masato
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (03) : 700 - 711
  • [8] Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China
    Liao, Shenling
    An, Kang
    Liu, Zhi
    He, He
    An, Zhenmei
    Su, Qiaoli
    Li, Shuangqing
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (09)
  • [9] Joint effects of sleep disturbance and renal function impairment on incident new-onset severe metabolic dysfunction-associated steatotic liver disease
    Tian, Tian
    Zeng, Jing
    Li, Yuan-Cheng
    Wang, Jing
    Zhang, Dan-Feng
    Wang, De-Guang
    Pan, Hai-Feng
    Fan, Jian-Gao
    Ni, Jing
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4724 - 4733
  • [10] METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) PREDICTS NEW ONSET OF CHRONIC KIDNEY DISEASE BETTER THAN DOES FATTY LIVER OR NAFLD
    Tanaka, Marenao
    Mori, Kazuma
    Takahashi, Satoko
    Higashiura, Yukimura
    Ohnishi, Hirofumi
    Hanawa, Nagisa
    Furuhashi, Masato
    JOURNAL OF HYPERTENSION, 2023, 41 : E333 - E334